Search results
-
IO Biotech looks for an interim injection
… & UBC + Keytruda (uncontrolled) Preliminary data at ESMO 2023; more data expected autumn 2024 PN-E40 …
- 06/27/2024 - 20:11 -
ASCO 2024 – full Evoke-01 result adds to Gilead’s Trodelvy problems
… and a secondary endpoint in Evoke-01. Source: ESMO 2023 & ASCO 2024. Conferences …
- 06/01/2024 - 22:08 -
EHA 2024 preview – Novartis doubles up
… Anti-CD123 NK cell engager S146 Had data at ESMO 2023 Roche Englumafusp alfa …
- 05/20/2024 - 18:11 -
J&J speeds into new bladder cancer trial
… pts with FGFR alterations Ph1 data at ESMO 2023: 87% CR rate in 15 pts in cohort 3 (BCG-naive) … BCG-experienced pts with FGFR mutations Data at ESMO 2023: 72% reduction in risk of recurrence/death in 73 … Ph2 Sunrise-1 in high-risk BCG-unresponsive pts, data at ESMO 2023: 77% CR rate in 30 pts Source: …
- 04/23/2024 - 13:00 -
BioNTech has some cancer convincing to do
… Car-T N/A Ph1/2 in solid tumours Data at ESMO 2023 showed promising efficacy, but with tox …
- 03/21/2024 - 13:20 -
AACR 2024 preview – clinical highlights and lowlights
… inhibitor 1L glioblastoma CT044 Had data at ESMO 2023 Cadonilimab Akeso Anti-PD-1 x CTLA-4 …
- 03/07/2024 - 15:52 -
Revolution pushes home its pan-KRAS advantage
… Medicines Multi-KRAS inhibitor Ph1 data at ESMO 2023 Ph3 could begin in 2024 in NSCLC & pancreatic …
- 02/28/2024 - 15:37 -
BioNTech bails out Autolus
… capacity Data with automated production at ESMO 2023 ; pivotal trial in germ cell tumours due to start …
- 02/08/2024 - 15:05 -
Jazz joins the KRAS band with Redx deal
… which produced promising data – with caveats – at ESMO 2023. Quanta is taking an interesting approach, with … KRAS G12D siRNA Ph2 in pancreatic cancer; ESMO 2023: no difference in OS vs chemo MRTX1133 … KRAS G12D inhibitor Lacklustre ph1 data at ESMO 2023 (1/18 PRs) ASP3082 Astellas KRAS G12D …
- 02/08/2024 - 13:03 -
A cancer pipeline cull from AbbVie
… payload) Ph1 in solid tumours Data at ESMO 2023 in NSCLC: ORR 14% in 3L & 10% in 2L … SHP2 inhibitor Ph1/2 in solid tumours Data at ESMO 2023 + glecirasib (KRAS G12C) in NSCLC: ORR 51% …
- 02/06/2024 - 13:49
